GHK-Cu vs BPC-157
Side-by-side comparison of GHK-Cu, BPC-157 — mechanism, dosing, half-life, side effects, and research status.
| Attribute | GHK-Cu Glycyl-L-Histidyl-L-Lysine Copper Complex Recovery | BPC-157 Body Protection Compound-157 Recovery |
|---|---|---|
| Basics | ||
| Molecular type | Copper-Binding Tripeptide | Gastric Pentadecapeptide |
| Amino acids | 3 | 15 |
| Molecular weight | 340.4 Da | 1,419.5 Da |
| Half-life | Short (minutes to hours) | ~4 hrs (SC) |
| Route(s) | Subcutaneous, Topical (skin), IV (research) | Subcutaneous, Intramuscular, Oral (research only) |
| Mechanism & Research | ||
| Primary mechanism | GHK-Cu forms a stable complex with copper(II), which is essential for its biological activity. The copper complex activates collagenase and other metalloproteinases that remodel damaged extracellular matrix while simulta… | BPC-157 exerts its primary effects through upregulation of the nitric oxide (NO) signalling pathway. By promoting NO synthase activity, it drives vasodilation and angiogenesis at injury sites, accelerating the delivery o… |
| Research status | Research Compound | Research Compound |
| Evidence summary | GHK-Cu is one of the most thoroughly researched cosmetic and wound-healing peptides. Topical GHK-Cu is commercially used in skincare. Deeper systemic applications (anti-aging, neuroprotection, systemic collagen support) … | The majority of BPC-157 research is preclinical (animal and in vitro). No large-scale randomised controlled trials in humans have been published as of 2026. The FDA's 2024 assessment noted insufficient human safety and e… |
| Protocol & Dosing | ||
| Typical dose | 1–2 mg/day (SC); topical as needed | 200–500 mcg per injection |
| Frequency | Daily | Once or twice daily |
| Duration | 8–12 weeks | 4–12 weeks |
| Timing | Any time of day | Near injury site when possible |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Not Prohibited | Prohibited (WADA S0) |
| Deeper reading | ||
| Related peptides | BPC-157, Epithalon, LL-37 | TB-500, GHK-Cu, KPV, Pentadeca Arginate |
| Full profile | Read full GHK-Cu profile → | Read full BPC-157 profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.